Wall Street analyst estimates for Annovis Bio, Inc. (ANVS): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 6 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 8 |
| Avg rating (1-5) | 0.75 |
Valuation Ratios
| Price / Book | -7.41 |
| EV / EBITDA | -0.82 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research & Development | $273370 | $111608 | $776256 | $3.1M | $8.5M | $16.5M | $38.8M | $20.0M | $25.2M |
| Selling, General & Admin | $409063 | $602329 | $829366 | $3.6M | $6.1M | $9.0M | $6.2M | $6.7M | $4.5M |
| Operating Expenses | $682433 | $713937 | $1.6M | $6.6M | $14.5M | $25.5M | $45.0M | $26.7M | $29.7M |
| Operating Income | -$682000 | -$714000 | -$1.6M | -$6.6M | -$14.5M | -$25.5M | -$45.0M | -$26.7M | -$29.7M |
| EBITDA | $84 | $66 | -$791000 | 0 | -$14.5M | -$25.3M | -$56.2M | -$22.7M | -$28.9M |
| Interest Expense | $84 | $66 | 0 | $47.2M | 0 | 0 | 0 | $1.9M | 0 |
| Pre-tax Income | -$682000 | -$714000 | -$991000 | -$5.5M | -$14.5M | -$25.3M | -$56.2M | -$24.6M | -$28.9M |
| Income Tax | 0 | -$132 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$682000 | -$714000 | -$991000 | -$5.5M | -$14.5M | -$25.3M | -$56.2M | -$24.6M | -$28.9M |
| EPS | $-0.10 | $-0.10 | $-0.14 | $-0.87 | $-1.90 | $-3.10 | $-6.23 | $-2.02 | $-1.40 |
| EPS (Diluted) | $-0.10 | $-0.10 | $-0.14 | $-0.87 | $-1.90 | $-3.10 | $-6.23 | $-2.31 | $-1.40 |
| Shares Outstanding (Diluted) | $6.8M | $6.8M | $6.8M | $6.3M | $7.6M | $8.2M | $9.0M | $12.2M | $20.6M |
Price
| Price | $1.04 |
| Market Cap | $44M |
| Exchange | NYSE |
| Country | US |
Related companies: ATNM · BCAB · BTAI · CELU · ELUT · EVAX · MAIA
Explore sector: Healthcare · Biotechnology
More sections of ANVS: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks